$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000173728722000035 Filed on May 04, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$86.00K	$61.00K	$51.00K
YoY Change	95.45%	-99.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.51M	$19.90M	$19.96M
YoY Change	3.87%	21.62%	16.53%
% of Gross Profit
Research & Development	$57.17M	$60.16M	$53.98M
YoY Change	9.33%	9.01%	3.36%
% of Gross Profit
Depreciation & Amortization	$3.675M	$3.692M	$4.242M
YoY Change	87.31%	92.49%	129.3%
% of Gross Profit
Operating Expenses	$76.68M	$80.05M	$73.94M
YoY Change	7.89%	11.89%	6.61%
Operating Profit	-$76.59M	-$79.99M
YoY Change	7.83%	140.93%
Interest Expense	$315.0K	$492.0K	$186.0K
YoY Change	-49.52%	-3.53%	-88.08%
% of Operating Profit
Other Income/Expense, Net	$1.492M	$142.0K	-$1.161M
YoY Change	1504.3%	-23.66%	50.78%
Pretax Income	-$74.79M	-$79.85M	-$74.87M
YoY Change	5.43%	141.82%	9.18%
Income Tax
% Of Pretax Income
Net Earnings	-$74.79M	-$79.85M	-$74.87M
YoY Change	5.43%	141.86%	9.18%
Net Earnings / Revenue	-86961.63%	-130901.64%	-146800.0%
Basic Earnings Per Share	-$0.52	-$0.56
Diluted Earnings Per Share	-$521.6K	-$0.56	-$537.8K
COMMON SHARES
Basic Shares Outstanding	143.6M shares	141.4M shares	142.5M shares
Diluted Shares Outstanding	143.4M shares	141.4M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$490.5M	$449.1M	$457.3M
YoY Change	-16.54%	-35.81%	-44.76%
Cash & Equivalents	$96.04M	$84.51M	$173.3M
Short-Term Investments	$394.5M	$364.5M	$284.0M
Other Short-Term Assets	$22.54M	$20.69M	$14.02M
YoY Change	55.81%	25.42%	-18.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$513.0M	$469.7M	$471.3M
YoY Change	-14.8%	-34.4%	-44.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$204.1M	$120.2M	$123.0M
YoY Change	62.65%	-2.39%	3.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$211.3M	$298.3M	$370.2M
YoY Change	-38.63%	5.07%	78.06%
Other Assets	$19.23M	$9.042M	$5.815M
YoY Change	229.9%	44.1%	12.5%
Total Long-Term Assets	$434.6M	$494.9M	$567.3M
YoY Change	-17.15%	6.89%	48.24%
TOTAL ASSETS
Total Short-Term Assets	$513.0M	$469.7M	$471.3M
Total Long-Term Assets	$434.6M	$494.9M	$567.3M
Total Assets	$947.6M	$964.6M	$1.039B
YoY Change	-15.89%	-18.19%	-15.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.713M	$8.708M	$10.26M
YoY Change	-11.74%	-41.46%	-1.3%
Accrued Expenses	$34.36M	$27.76M	$37.50M
YoY Change	-0.95%	-30.07%	-16.49%
Deferred Revenue	$104.0K	$406.0K	$423.0K
YoY Change	-65.9%	69.87%	-98.92%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.91M	$36.88M	$48.17M
YoY Change	-2.37%	-32.77%	-48.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.8M	$3.490M	$4.125M
YoY Change	1666.63%	25.04%	33.8%
Total Long-Term Liabilities	$100.8M	$3.490M	$4.125M
YoY Change	1666.63%	25.04%	33.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.91M	$36.88M	$48.17M
Total Long-Term Liabilities	$100.8M	$3.490M	$4.125M
Total Liabilities	$145.7M	$109.4M	$122.2M
YoY Change	41.57%	0.13%	-17.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.053B	-$983.2M	-$903.3M
YoY Change	40.4%	44.72%	39.76%
Common Stock	$1.871B	$1.848B	$1.822B
YoY Change	5.46%	5.63%	5.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$801.9M	$855.2M	$916.4M
YoY Change
Total Liabilities & Shareholders Equity	$947.6M	$964.6M	$1.039B
YoY Change	-15.89%	-18.19%	-15.41%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$74.79M	-$79.85M	-$74.87M
YoY Change	5.43%	141.86%	9.18%
Depreciation, Depletion And Amortization	$3.675M	$3.692M	$4.242M
YoY Change	87.31%	92.49%	129.3%
Cash From Operating Activities	-$42.53M	-$68.24M	-$45.44M
YoY Change	3.31%	38.33%	355.73%
INVESTING ACTIVITIES
Capital Expenditures	-$1.374M	$1.902M	-$736.0K
YoY Change	-87.4%	-70.56%	-95.77%
Acquisitions
YoY Change
Other Investing Activities	$55.41M	-$20.48M	$29.99M
YoY Change	56.1%	-119.83%	-24.3%
Cash From Investing Activities	$54.03M	-$22.38M	$29.25M
YoY Change	119.72%	-123.12%	31.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	24.00K	$1.814M	322.0K
YoY Change	-99.25%	-69.99%	-97.52%
NET CHANGE
Cash From Operating Activities	-42.53M	-$68.24M	-45.44M
Cash From Investing Activities	54.03M	-$22.38M	29.25M
Cash From Financing Activities	24.00K	$1.814M	322.0K
Net Change In Cash	11.53M	-$88.80M	-15.86M
YoY Change	-186.29%	-265.94%	-162.9%
FREE CASH FLOW
Cash From Operating Activities	-$42.53M	-$68.24M	-$45.44M
Capital Expenditures	-$1.374M	$1.902M	-$736.0K
Free Cash Flow	-$41.16M	-$70.14M	-$44.70M
YoY Change	35.99%	25.72%	-700.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20220331#AccruedAndOtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20220331#AccruedAndOtherLiabilitiesCurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38693
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2022Q1	dei	City Area Code CityAreaCode	650
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	457-2700
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	ALLO
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	143600314	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84514000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173314000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	364536000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	283988000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20694000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14021000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	469744000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	471323000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	284093000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	352179000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	57057000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58030000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	120200000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	122990000	USD
CY2022Q1	us-gaap	Assets Assets	964632000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9042000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5815000	USD
CY2022Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	14204000	USD
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	18005000	USD
CY2021Q4	us-gaap	Assets Assets	1038634000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8708000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10255000	USD
CY2022Q1	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	27763000	USD
CY2021Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	37496000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	406000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	423000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	36877000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48174000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69035000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69929000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3490000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4125000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	109402000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	122228000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143569902	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143569902	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142623065	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142623065	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	143000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	142000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1847534000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1822179000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	916406000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	964632000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-983198000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-903348000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9249000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2567000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	855230000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1038634000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38345000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60156000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55183000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19897000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16363000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	80053000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	71546000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-79992000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-33201000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	492000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	511000	USD
CY2022Q1	us-gaap	Other Expenses OtherExpenses	350000	USD
CY2021Q1	us-gaap	Other Expenses OtherExpenses	325000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	142000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	186000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-79850000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-33015000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6682000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-369000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86532000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33384000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141356306	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141356306	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132165014	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132165014	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	916406000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	283000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1228000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22315000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1530000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-79850000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6682000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	855230000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4060000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	710000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16792000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1984000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-33015000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-369000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1069779000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-79850000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-33015000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	22315000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	16792000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	3692000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1918000	USD
CY2022Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1332000	USD
CY2021Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1911000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	466000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	2007000	USD
CY2022Q1	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-3800000	USD
CY2021Q1	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-325000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6673000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-740000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3114000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	799000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-505000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4152000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9048000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4314000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-17000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38753000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-635000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-292000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68237000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49328000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1902000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6461000	USD
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15938000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	68680000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	268249000	USD
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	89155000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	149052000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22377000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	96798000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	283000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4060000	USD
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1531000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1984000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1814000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6044000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-88800000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53514000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183606000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192800000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94806000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246314000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	725000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8299000	USD
CY2022Q1	allo	Capitalized Costs CapitalizedCosts	111000	USD
CY2021Q1	allo	Capitalized Costs CapitalizedCosts	277000	USD
CY2022Q1	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	1980000	USD
CY2021Q1	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	966000	USD
CY2022Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	325000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	1111000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is an immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had cash and cash equivalents and investments of $733.1 million as of March 31, 2022. Since inception through March 31, 2022, the Company has incurred cumulative net losses of $983.2 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected.
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	733100000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-983200000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	692748000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8813000	USD
CY2022Q1	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	683941000	USD
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	35312000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	364536000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	284093000	USD
CY2022Q1	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	683941000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	754157000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2156000	USD
CY2021Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	752034000	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	115867000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	283988000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	352179000	USD
CY2021Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	752034000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1900000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1900000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	147253000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	146351000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27053000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23361000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	120200000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	122990000	USD
CY2018Q3	allo	Area Of New Office Building AreaOfNewOfficeBuilding	68000	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P127M
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2022Q1	us-gaap	Tenant Improvements TenantImprovements	5000000	USD
CY2021Q4	allo	Additional Area Of New Office Building AdditionalAreaOfNewOfficeBuilding	47566	sqft
CY2018Q4	allo	Area Of New Office Building AreaOfNewOfficeBuilding	14943	sqft
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P124M
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2018Q4	allo	Tenant Improvement Allowance TenantImprovementAllowance	800000	USD
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6000000	USD
CY2021Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6000000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3588000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	73129000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3200000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69035000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69929000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	72623000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2122000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1862000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	455000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	327000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	2577000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	2189000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2000000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6023000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8257000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8523000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8557000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8598000	USD
CY2022Q1	allo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	65798000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	105756000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33133000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	72623000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0636
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y11M26D
CY2020Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P20Y
CY2020Q3	allo	Lessee Finance Lease Payment Upon Contract Termination LesseeFinanceLeasePaymentUponContractTermination	4300000	USD
CY2022Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	2800000	USD
CY2022Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	14200000	USD
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	18000000	USD
CY2022Q1	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14142447	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22315000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16792000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	293594	shares
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5300000	USD
CY2022Q1	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2300000	USD
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2900000	USD
CY2022Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	1900000	USD
CY2021Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	2500000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23561869	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21900607	shares

Files In Submission

Name	View Source	Status
0001737287-22-000035-index-headers.html	Edgar Link	pending
0001737287-22-000035-index.html	Edgar Link	pending
0001737287-22-000035.txt	Edgar Link	pending
0001737287-22-000035-xbrl.zip	Edgar Link	pending
allo-20220331.htm	Edgar Link	pending
allo-20220331.xsd	Edgar Link	pending
allo-20220331xex311.htm	Edgar Link	pending
allo-20220331xex312.htm	Edgar Link	pending
allo-20220331xex321.htm	Edgar Link	pending
allo-20220331_cal.xml	Edgar Link	unprocessable
allo-20220331_def.xml	Edgar Link	unprocessable
allo-20220331_htm.xml	Edgar Link	completed
allo-20220331_lab.xml	Edgar Link	unprocessable
allo-20220331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2022 Q2 Form 10-Q Financial Statement

#000173728722000035 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2022 Q2 Form 10-Q Financial Statement

#000173728722000035 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo